These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22847535)

  • 81. Visualization of HER2-specific breast cancer intratumoral heterogeneity using
    Sasada S; Kurihara H; Kinoshita T; Yoshida M; Honda N; Shimoi T; Shimomura A; Yonemori K; Shimizu C; Hamada A; Kanayama Y; Watanabe Y; Fujiwara Y; Tamura K
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2146-2147. PubMed ID: 28770275
    [No Abstract]   [Full Text] [Related]  

  • 82. HER2 as a therapeutic target in the gastric cancer: is it sufficient?
    Chaturvedi R; Singh AB
    Indian J Gastroenterol; 2012 Jun; 31(3):103-5. PubMed ID: 22763895
    [No Abstract]   [Full Text] [Related]  

  • 83. Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer.
    Oguz A; Keskin GS; Colak D; Altundag O; Akcali Z
    J Clin Oncol; 2016 Feb; 34(6):639-40. PubMed ID: 26644534
    [No Abstract]   [Full Text] [Related]  

  • 84. Reply to D. Serraino et al.
    Partridge AH; Gelber S; Gelber R
    J Clin Oncol; 2014 Jan; 32(2):161. PubMed ID: 24323031
    [No Abstract]   [Full Text] [Related]  

  • 85. The quality of life of young women with nonmetastatic breast cancer and their partners': specific needs require development of specific questionnaires for each of them.
    Vanlemmens L; Christophe V; Fournier E; Dauchy S; Boinon D; Toudic-Emily F; Duffour B; Machavoine JL; Reich M; Bonneterre J; Domont J; Kaci FA; Antoine P
    Breast J; 2012; 18(2):182-4. PubMed ID: 22284212
    [No Abstract]   [Full Text] [Related]  

  • 86. Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina.
    Gadan MA; González SJ; Batalla M; Olivera MS; Policastro L; Sztejnberg ML
    Appl Radiat Isot; 2015 Oct; 104():155-9. PubMed ID: 26164147
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Palbociclib: an approval at last for HER2-negative breast cancer.
    Zerdes I; Ziogas DE; Lykoudis EG; Roukos DH
    Future Oncol; 2016 May; 12(9):1097-100. PubMed ID: 26987714
    [No Abstract]   [Full Text] [Related]  

  • 88. Reply to A. Oguz et al.
    O'Sullivan CC; Holmes E; Campbell C; Bradbury I; Zujewski JA; Gelber RD
    J Clin Oncol; 2016 Feb; 34(6):640-1. PubMed ID: 26644531
    [No Abstract]   [Full Text] [Related]  

  • 89. Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007.
    Pegram M; Perez EA; Piccart M; Spector N
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S131-41. PubMed ID: 18777952
    [No Abstract]   [Full Text] [Related]  

  • 90. Setting the bar for adjuvant treatment of melanoma.
    Sondak VK; Gibney GT
    Lancet Oncol; 2014 May; 15(6):547-8. PubMed ID: 24745697
    [No Abstract]   [Full Text] [Related]  

  • 91. Intratumoral HER2 heterogeneity in breast cancer.
    Pegram M
    Clin Adv Hematol Oncol; 2020 Sep; 18(9):535-537. PubMed ID: 33006582
    [No Abstract]   [Full Text] [Related]  

  • 92. Breast feeding reduces risk of breast cancer recurrence, study finds.
    Mayor S
    BMJ; 2015 Apr; 350():h2325. PubMed ID: 25929482
    [No Abstract]   [Full Text] [Related]  

  • 93. Significance of tumor biology on local control in breast cancer.
    Goyal S; Haffty BG
    Oncology (Williston Park); 2014 Nov; 28(11):930-8. PubMed ID: 25403628
    [No Abstract]   [Full Text] [Related]  

  • 94. Pembrolizumab shows potential in breast cancer.
    Cancer Discov; 2015 Feb; 5(2):100-1. PubMed ID: 25656879
    [No Abstract]   [Full Text] [Related]  

  • 95. Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA.
    Mortimer JE; Shively JE
    J Nucl Med; 2019 Jan; 60(1):23-25. PubMed ID: 30573641
    [No Abstract]   [Full Text] [Related]  

  • 96. Are bilateral and unilateral interval breast cancers different?
    Altundag K
    J BUON; 2018; 23(3):836-837. PubMed ID: 30003762
    [No Abstract]   [Full Text] [Related]  

  • 97. Correspondence to "Locoregional therapy in de novo metastatic breast cancer: Systematic review and meta-analysis, written by Reinhorn D et al. In The Breast Journal 58 (2021) 173-181".
    Soran A; Ozbas S; Dogan L; Isik A; Sezgin E;
    Breast; 2021 Dec; 60():304-305. PubMed ID: 34654601
    [No Abstract]   [Full Text] [Related]  

  • 98. Dostarlimab: A light of hope espied amidst an age-long combat against cancer.
    Gul A
    J Pak Med Assoc; 2023 Mar; 73(3):740. PubMed ID: 36932807
    [No Abstract]   [Full Text] [Related]  

  • 99. Locoregional treatment of breast cancer: where to next?
    Mittendorf EA; Smith BD
    Oncology (Williston Park); 2011 Aug; 25(9):817, 821-2. PubMed ID: 21936443
    [No Abstract]   [Full Text] [Related]  

  • 100. Progress but not perfection: ongoing efforts to optimize locoregional treatments for breast cancer.
    McLaughlin S
    Oncology (Williston Park); 2011 Aug; 25(9):822, 825, 829-30. PubMed ID: 21936444
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.